chang
influenza
virus
requir
regular
reformul
strainspecif
influenza
vaccin
vaccin
base
conserv
antigen
provid
broader
protect
influenza
matrix
protein
highli
conserv
across
influenza
subtyp
evalu
efficaci
vaccin
candid
vaccin
mice
peptid
wide
share
consensu
sequenc
vaccin
induc
antibodi
crossreact
diverg
peptid
subtyp
dna
vaccin
express
fulllength
consensussequ
induc
antibodi
respons
protect
challeng
lethal
influenza
mice
prime
boost
recombin
adenoviru
express
enhanc
antibodi
respons
crossreact
human
avian
sequenc
produc
tcell
respons
primeboost
vaccin
confer
broad
protect
challeng
lethal
influenza
includ
strain
vaccin
key
sequenc
repres
may
provid
broad
protect
influenza
earli
develop
influenza
vaccin
antigen
match
circul
strain
pose
extraordinari
challeng
rapidli
develop
pandem
would
shorten
time
strain
identif
vaccin
prepar
meanwhil
antigen
chang
would
continu
moreov
need
immun
entir
naiv
popul
would
exacerb
problem
vaccin
product
suppli
vaccin
base
conserv
antigen
would
requir
predict
strain
would
circul
approach
season
could
avoid
hurri
manufactur
respons
outbreak
test
vaccin
dna
construct
express
conserv
influenza
nucleoprotein
np
np
plu
matrix
induc
antibodi
tcell
respons
protect
heterosubtyp
virus
despit
virul
rapid
kinet
challeng
infect
dna
vaccin
np
achiev
limit
protect
viru
strain
isol
human
outbreak
hong
kong
gene
influenza
encod
protein
highli
conserv
capsid
protein
ion
channel
protein
contain
small
ectodomain
make
target
antibodybas
immun
abil
monoclon
antibodi
mab
reduc
viral
replic
implic
particular
vaccin
target
vaccin
candid
explor
includ
peptidecarri
conjug
baculovirusexpress
fusion
protein
multipl
antigen
peptid
dna
construct
potenti
express
studi
mice
protect
challeng
homolog
heterosubtyp
virus
even
heterosubtyp
virus
sequenc
ident
vaccin
construct
differ
amino
acid
although
human
influenza
virus
subtyp
share
ident
consensu
sequenc
influenza
virus
studi
conjug
vaccin
serum
antibodi
specif
crossreact
peptid
subtyp
avian
virus
mismatch
anoth
studi
monoclon
polyclon
antibodi
react
subset
avian
sequenc
although
recent
studi
use
peptideliposom
vaccin
subtyp
protect
influenza
virus
includ
subtyp
includ
match
challeng
virus
prior
work
document
protect
challeng
influenza
virus
sequenc
differ
substanti
immun
antigen
prioriti
given
develop
vaccin
offer
broad
protect
multipl
influenza
subtyp
includ
inde
develop
conservedantigen
vaccin
specif
vaccin
part
us
depart
health
human
servic
pandem
influenza
plan
wwwhhsgovpandemicflu
plan
therefor
evalu
vaccin
efficaci
diverg
challeng
virus
femal
balbcanncr
mice
purchas
divis
cancer
treatment
nation
cancer
institut
frederick
maryland
usa
institut
anim
care
use
committe
approv
protocol
anim
experi
influenza
virus
use
viru
stock
propag
allanto
caviti
embryon
hen
egg
h
h
afm
prepar
pool
homogen
lung
balbc
mice
infect
day
previous
experi
subtyp
conduct
biosafeti
level
enhanc
contain
peptid
methionin
synthes
coohtermin
cystin
residu
conjug
maleimideactiv
keyhol
limpet
hemocyanin
klh
vaccin
peptid
also
synthes
without
coohtermin
cystin
use
antibodi
tcell
assay
influenza
peptid
synthes
core
facil
center
biolog
evalu
research
us
food
drug
administr
sever
acut
respiratori
syndrom
sar
matrix
peptid
provid
nation
institut
health
plasmid
recombin
adenovir
rad
vector
express
bnp
anp
describ
plasmid
contain
entir
gene
plasmid
term
gener
follow
plasmid
deriv
pcr
vector
previous
gener
viru
revers
transcriptionpcr
modifi
sequenc
wide
share
sequenc
fulllength
consensu
cdna
kozak
sequenc
end
gener
overlap
dna
fragment
subclon
obtain
materi
transfer
agreement
vical
inc
san
diego
ca
usa
sequenc
insert
confirm
restrict
digest
sequenc
analysi
replicationincompet
adenoviru
express
protein
consensu
sequenc
construct
use
gateway
clone
virapow
adenovir
express
system
invitrogen
carlsbad
ca
usa
accord
manufactur
instruct
briefli
cdna
clone
pcr
pentrdtopo
gateway
vector
transfer
adenovir
gateway
vector
lr
clonas
invitrogen
reaction
give
integr
proper
insert
clone
cdna
confirm
sequenc
gener
transfect
cell
express
confirm
immunohistochem
stain
madindarbi
canin
kidney
cell
polyclon
sera
data
shown
hightit
stock
rad
prepar
viraquest
inc
north
liberti
ia
usa
adenoviru
stock
store
sucrosephosphatebuff
salin
pb
particlesml
confirm
neg
replicationcompet
adenoviru
passag
nonpermiss
cell
mice
given
intraperiton
inject
peptideklh
unconjug
klh
complet
freund
adjuv
emulsifi
antigen
pb
three
week
later
mice
given
intraperiton
booster
inject
peptideklh
incomplet
freund
adjuv
day
later
blood
collect
inject
start
week
age
peptid
week
age
dna
dna
vaccin
dose
unless
note
otherwis
figur
legend
lowendotoxin
pb
accugen
cambrex
east
rutherford
nj
usa
given
intramuscularli
quadricep
half
leg
dose
week
apart
experi
mice
given
booster
inject
rad
intramuscularli
dose
particlesmous
week
last
dose
dna
challeng
viru
pb
administ
intranas
anesthet
mice
isofluran
ketaminexylazin
use
mice
challeng
subtyp
report
lethal
dose
ld
subtyp
determin
naiv
balbc
mice
anesthet
may
vari
actual
ld
older
vaccin
mice
challeng
subtyp
administ
intranas
mice
anesthet
tertamyl
alcohol
avertin
aldrich
chemic
co
milwauke
wi
usa
mice
kill
lung
could
harvest
other
monitor
bodi
weight
death
monitor
continu
anim
die
recov
indic
bodi
weight
acut
deplet
lymphocyt
popul
mab
treatment
day
rel
day
challeng
perform
describ
previous
use
mab
specif
mous
specif
mous
specif
human
leukocyt
antigen
neg
control
splenocyt
analyz
day
challeng
next
inject
flow
cytometri
confirm
complet
vivo
tcell
deplet
describ
elisa
antibodi
perform
plate
coat
synthet
peptid
moll
borat
buffer
moll
salin
rest
procedur
describ
naiv
mice
given
intraperiton
inject
pool
serum
ml
per
mous
mice
immun
plu
match
ad
booster
control
mice
bnpdna
hk
peptideklh
conjug
viru
mice
challeng
moder
dose
viru
day
serum
transfer
antibodi
level
recipi
measur
cell
enrich
neg
select
use
magnet
bead
briefli
splenocyt
deplet
erythrocyt
label
biotinyl
antimous
pannk
antibodi
bd
pharmingen
san
diego
ca
usa
label
cell
incub
streptavidin
microbead
miltenyi
biotec
auburn
ca
usa
unlabel
cell
label
nont
cell
separ
miltenyi
automac
system
accord
manufactur
instruct
assay
detect
tcell
respons
peptid
elispot
ip
plate
millipor
billerica
usa
coat
hank
balanc
salt
solut
hyclon
logan
ut
usa
contain
mab
bd
pharmingen
incub
overnight
membran
wash
block
medium
contain
fetal
bovin
serum
min
room
temperatur
splenocyt
deplet
erythrocyt
ad
well
dilut
start
cellswel
peptid
ad
final
concentr
incub
h
bound
detect
biotinyl
mab
bd
pharmingen
spot
develop
use
alkalin
phosphataselabel
streptavidin
tetrazolium
substrat
kirkegaard
perri
laboratori
gaithersburg
md
usa
count
elispot
reader
zeiss
thornwood
ny
usa
lung
homogen
ml
steril
pb
clarifi
centrifug
titrat
viru
infect
egg
infecti
dose
eid
assay
describ
limit
viru
detect
log
eid
ml
challeng
viru
stock
titrat
madindarbi
canin
kidney
cell
describ
previous
serolog
assay
detect
cell
perform
multipl
time
compar
result
vaccin
repeat
independ
group
note
figur
legend
perform
use
number
anim
per
group
adequ
statist
signific
lung
viru
titer
compar
use
analysi
varianc
logtransform
data
follow
pairwis
multipl
comparison
holmsidak
method
weight
loss
challeng
compar
survivor
day
also
use
analysi
varianc
follow
pairwis
multipl
comparison
holmsidak
method
overestim
bodi
weight
group
death
anim
die
would
low
bodi
weight
affect
averag
especi
neg
control
group
nonetheless
differ
vaccin
group
signific
instanc
state
comparison
cumul
surviv
rate
use
logrank
test
follow
pairwis
multipl
comparison
use
holmsidak
method
overal
signific
level
holmsidak
test
p
statist
analys
perform
sigmastat
softwar
systat
softwar
point
richmond
ca
usa
proofofconcept
studi
peptid
repres
addit
viral
ectodomain
tabl
conjug
klh
use
immun
balbc
mice
immun
serum
sampl
analyz
antibodi
elisa
plate
coat
synthet
peptid
sequenc
virus
subtyp
serum
klhimmun
mice
react
peptid
serum
sampl
react
peptid
figur
c
crossreact
lower
hk
peptid
figur
mice
challeng
either
afm
monitor
weight
loss
measur
ill
death
weight
loss
consist
hierarchi
protect
base
sequenc
similar
data
shown
differ
control
mice
statist
signific
group
mice
vaccin
surviv
challeng
afm
hk
klh
vaccin
provid
incomplet
protect
figur
b
investig
whether
like
peptid
dna
vaccin
could
protect
virus
quit
diverg
sequenc
test
mand
efficaci
mdna
sequenc
protect
challeng
figur
consensu
sequenc
also
protect
challeng
howev
data
shown
challeng
afm
efficaci
mdna
figur
previous
shown
np
vaccin
boost
rad
induc
potent
antibodi
tcell
especi
respons
dna
vaccin
alon
protect
challeng
highli
pathogen
subtyp
investig
whether
boost
rad
would
also
enhanc
immun
gene
consensu
sequenc
clone
replicationdefici
ad
construct
mice
prime
dna
boost
control
bnpad
two
week
later
serum
sampl
collect
assay
immunoglobulin
ig
g
elisa
peptid
figur
mice
given
booster
dramat
greater
igg
antibodi
respons
mice
given
either
compon
alon
figur
moreov
igg
crossreact
amino
acid
differ
figur
amino
acid
differ
figur
found
serum
mice
given
crossreact
even
greater
serum
mice
given
serum
sampl
howev
crossreact
hk
amino
acid
differ
figur
although
serum
mice
immun
hk
klh
posit
control
react
strongli
data
shown
protect
immun
due
vaccin
test
challeng
highdos
afm
moder
dose
viru
mice
vaccin
surviv
challeng
afm
viru
mice
vaccin
bnpdnabnpad
surviv
challeng
none
surviv
challeng
afm
figur
b
thu
primeboost
vaccin
protect
challeng
virus
sequenc
similar
diverg
vaccin
tcell
respons
observ
immun
cdna
express
fulllength
protein
might
induc
addit
antibodi
tcell
respons
induc
peptid
address
contribut
tcell
respons
immun
mice
primeboost
acut
deplet
cell
challeng
period
lymphocyt
deplet
confirm
complet
residu
splenic
cell
data
shown
bnp
control
mice
die
infect
day
challeng
mice
treat
control
mab
sfr
surviv
figur
individu
deplet
cell
abrog
protect
deplet
cell
togeth
partial
statist
significantli
abrog
protect
figur
left
protect
significantli
differ
bnp
control
mice
thu
challeng
condit
cell
import
immun
report
natur
killer
nk
cell
depend
found
mice
deplet
nk
cell
antibodi
protect
similarli
control
data
shown
thu
nk
cell
may
play
role
requir
condit
studi
given
effect
tcell
deplet
test
vitro
cell
elispot
assay
show
posit
respons
aminotermin
peptid
spleen
cell
mice
immun
figur
data
shown
spleen
cell
fraction
magnet
bead
separ
see
method
nontcel
fraction
respond
unfraction
cell
tcell
fraction
maintain
strong
respons
figur
basi
inform
previou
studi
see
discuss
test
abil
antibodi
induc
dna
primead
boost
passiv
transfer
protect
mice
given
serum
mice
surviv
given
control
bnpimmun
serum
surviv
figur
p
log
rank
passiv
serum
antibodi
primeboost
immun
mice
also
confer
signific
protect
weight
loss
figur
protect
challeng
afm
viru
sequenc
quit
diverg
immun
sequenc
encourag
test
whether
lung
viru
titer
measur
viru
titer
mice
vaccin
anp
significantli
reduc
compar
control
mice
figur
remain
mice
monitor
weight
loss
surviv
weight
loss
less
mice
vaccin
anp
control
mice
figur
bnpimmun
mice
die
infect
day
postchalleng
anpimmun
mice
mous
surviv
figur
result
indic
vaccin
induc
crossreact
antibodi
respons
virusspecif
tcell
respons
protect
challeng
lethal
heterolog
viru
found
previou
studi
vaccin
found
strong
antibodi
respons
conserv
region
antibodi
serum
mice
immun
dna
suggest
express
plasmid
shown
howev
reactiv
could
due
amino
acid
portion
share
sequenc
explor
possibl
conjug
immun
result
antibodi
crossreact
avian
sequenc
test
found
crossreact
peptid
consider
sequenc
diverg
human
influenza
consensu
immun
induc
antibodi
reactiv
peptid
less
reactiv
hk
howev
immun
hk
klh
induc
antibodi
reactiv
peptid
pattern
parallel
result
liu
et
al
howev
neither
fan
et
al
liu
et
al
investig
protect
challeng
subtyp
lethal
challeng
studi
peptid
conjug
protect
subtyp
viru
also
subtyp
viru
afm
latter
viru
virul
mice
sequenc
amino
acid
differ
consensu
thu
diverg
consensu
sequenc
sequenc
encourag
broad
crossreact
crossprotect
expand
studi
dna
vaccin
dna
primead
boost
regimen
approach
advantag
provid
epitop
peptid
immun
relev
tcell
immun
use
consensu
dna
vaccin
without
ad
boost
saw
crossreact
avian
peptid
hk
although
crossreact
low
hk
peptid
tcell
respons
peptid
detect
elispot
sever
studi
shown
antibodi
mediat
protect
influenza
infect
vivo
agreement
studi
found
serum
antibodi
induc
peptid
conjug
primeboost
vaccin
could
transfer
protect
naiv
recipi
found
cell
also
import
deplet
cell
challeng
period
reduc
protect
higher
challeng
dose
could
reflect
memori
cell
demonstr
spleen
peripher
blood
elispot
concurr
tcell
respons
challeng
viru
supplement
protect
effect
antibodi
lethal
challeng
studi
consensu
dna
rad
construct
could
protect
also
afm
viru
quit
diverg
sequenc
furthermor
could
protect
mice
challeng
isol
fatal
human
case
dose
lethal
control
mice
viru
replic
lung
ill
reflect
loss
bodi
weight
also
reduc
immun
protect
challeng
subtyp
remain
explor
serolog
result
hk
peptid
suggest
result
studi
might
differ
basi
sequenc
variat
express
construct
variou
sequenc
could
use
vaccin
observ
protect
across
substanti
sequenc
diverg
mean
vaccin
might
also
protect
circul
subtyp
addit
advantag
protect
across
substanti
diverg
potenti
protect
vaccin
unexpect
subtyp
could
caus
pandem
one
concern
vaccin
possibl
escap
mutant
studi
forc
escap
mutant
found
limit
divers
indic
structur
constraint
perhap
due
requir
structur
encod
segment
may
limit
drift
crossreact
protect
efficaci
antibodi
suggest
mab
could
use
antivir
therapi
featur
combin
constraint
structur
highlight
potenti
mab
inhibit
replic
influenza
virus
includ
strain
although
tradit
drug
eg
amantadin
led
drug
resist
mutat
confer
resist
within
transmembran
region
may
fewer
structur
constraint
ectodomain
primeboost
regimen
intend
combin
vaccin
addit
antigen
rather
act
standalon
vaccin
exampl
primeboost
vaccin
conserv
np
highli
protect
figur
use
multipl
antigen
sever
advantag
reduc
likelihood
escap
mutant
better
coverag
human
leukocyt
antigen
haplotyp
genet
divers
human
popul
broader
spectrum
immun
respons
mechan
antibodi
perhap
domin
cytotox
lymphocyt
np
figur
role
tand
bcell
immun
matrix
protein
specif
protect
immun
mice
per
group
immun
bnpdna
boost
match
adenoviru
ad
describ
method
three
week
ad
boost
group
acut
deplet
cell
monoclon
antibodi
mab
given
control
mab
describ
method
mice
challeng
lethal
dose
ld
compar
cumul
surviv
rate
sfr
control
surviv
rate
differ
significantli
mice
deplet
tcell
subset
p
logrank
although
protect
remain
differ
significantli
bnp
control
p
logrank
b
mice
immun
describ
five
month
mice
receiv
ad
boost
spleen
cell
isol
pool
immun
mice
n
fraction
tcell
nontcel
popul
assay
produc
cell
enzymelink
immunosorb
spot
assay
describ
method
c
serum
collect
immun
mice
passiv
transfer
intraperiton
naiv
balbc
mice
per
group
recipi
challeng
ld
monitor
surviv
c
weight
loss
cumul
surviv
rate
mice
given
immun
serum
serum
hk
keyhol
limpet
hemocyaninimmun
serum
significantli
higher
mice
given
bnpdnabnpadimmun
serum
p
log
rank
weight
loss
primeboost
differ
bnp
primeboost
day
p
analysi
varianc
p
holmsidak
pairwis
multipl
comparison
sar
sever
acut
respiratori
syndrom
vaccin
base
conserv
antigen
intend
replac
strainmatch
vaccin
induc
neutral
antibodi
thu
prevent
infect
howev
strainmatch
vaccin
may
difficult
produc
adequ
quantiti
short
time
period
continu
antigen
drift
may
render
ineffect
vaccin
describ
base
might
reduc
death
sever
diseas
strainmatch
vaccin
prepar
could
enhanc
protect
afford
inactiv
vaccin
immunogen
safeti
studi
peopl
need
evalu
approach
